Company: NCEL
Filing Date: 2025-06-23
Form Type: F-4/A
Source: 0001213900-25-056787
Chunk: 41

Company: NewcelX Ltd.
Filing Date: 2025-06-23
Form: F-4/A
Chunk 41
---
6,661,646. On December19, 2024, the date of the determinations of the values for each company by Moore, Kadimastem’s market capitalization was $22,329,905 and its closing price per share was $3.161, each as calculated and converted from NIS to dollars based on a conversion rate of 3.645 NIS to 1 dollar on such day. On December19, 2024, NLS’s closing price per NLS Common Share on the Nasdaq was $2.38, with a market capitalization of $4.35million. For more information, please see the section entitled “ Fairness Opinions and Valuation Reports of Moore Financial Consulting” in this proxy statement/prospectus. Q.What is the anticipated business of the combined company? The Merger Agreement provides that, upon the terms and subject to the conditions thereof, following the Closing, NLS shall work diligently to dispose of any intellectual property, assets, rights, contracts, agreements, leases, arrangements (regardless of form), approvals, licenses, permits, whether current or future, whether or not contingent, of NLS and its subsidiaries related solely to any product candidate of NLS and its subsidiaries, other than NLS’s Dual Orexin Agonist, or DOXA, platform. We refer herein to such assets to be disposed as the Legacy Assets. Kadimastem’s current business activities will continue to be carried out by Kadimastem as a wholly -ownedsubsidiary of NLS. Q.What vote is required to approve each proposal at the NLS Meeting? The following voting majorities are required on the individual proposals of the draft NLS Meeting invitation: The following table summarizes the minimum vote needed to approve each proposal and the effect of abstentions and broker non -votes.

| Proposal                                                                                                           |     | Votes Required                                                                                          |     | Effects of                                                                                  
 Abstentions and                                                                             
 Broker Non-Votes                                                                            |
| Proposal 1 (Advisory vote: Approval of Merger Agreement)                                                           |     | The majority of the shares bearing voting rights represented.                                           |     | “Abstentions and broker non-votes will have the same effect as a vote AGAINST the proposal” |
| Proposal 2 (2. Ordinary Share Capital Increase with Contribution of the Kadimastem Shares to Implement the Merger) |     | At least two-thirds of the votes represented and a majority of the nominal value of shares represented. |     |